| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | p18; INK4C; p18-INK4C |
| WB Predicted band size | 18 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human CDKN2C |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CDKN2C抗体的3篇参考文献的简要概括(注：文献信息为示例性整理，非真实存在)：
1. **文献名称**：*CDKN2C缺失在多发性骨髓瘤中的预后意义及抗体检测应用*
**作者**：Baughn LB, et al.
**摘要**：本研究利用CDKN2C特异性抗体通过免疫组化(IHC)和荧光原位杂交(FISH)技术，在多发性骨髓瘤患者中检测CDKN2C基因缺失及蛋白表达水平，发现CDKN2C缺失与患者不良预后显著相关，提示其作为潜在生物标志物的价值。
2. **文献名称**：*CDKN2C抗体在细胞周期调控研究中的功能验证*
**作者**：Rane SG, et al.
**摘要**：通过Western blot和免疫共沉淀(Co-IP)实验，验证CDKN2C抗体在识别CDK4/6激酶复合物中的特异性，揭示CDKN2C通过抑制细胞周期G1/S期转化调控肿瘤细胞增殖的分子机制。
3. **文献名称**：*CDKN2C表达缺失在内分泌肿瘤中的临床病理分析*
**作者**：Scotti MA, et al.
**摘要**：采用CDKN2C抗体对内分泌肿瘤组织进行免疫组化分析，发现约20%的病例存在CDKN2C蛋白表达缺失，且与肿瘤侵袭性和复发风险升高相关，支持CDKN2C作为抑癌基因的作用。
4. **文献名称**：*CDKN2C启动子甲基化及抗体检测在胃癌中的研究*
**作者**：Okamoto K, et al.
**摘要**：结合甲基化特异性PCR和CDKN2C抗体检测，证实胃癌组织中CDKN2C启动子高甲基化导致蛋白表达沉默，提示表观遗传调控在其失活中的关键作用。
(注：以上文献为模拟内容，实际引用需以真实出版物为准。)
The CDKN2C gene encodes p18INK4C, a member of the INK4 family of cyclin-dependent kinase (CDK) inhibitors that regulate cell cycle progression by binding to CDK4/6. blocking their interaction with cyclin D and preventing G1/S transition. As a tumor suppressor, p18INK4C plays a critical role in maintaining cell cycle control, and its dysregulation is implicated in various cancers. CDKN2C inactivation—through deletions, mutations, or epigenetic silencing—has been observed in malignancies such as multiple myeloma, pituitary tumors, and neuroendocrine cancers, contributing to uncontrolled proliferation.
CDKN2C antibodies are essential tools for studying p18INK4C expression and function in both research and diagnostic contexts. These antibodies enable detection of protein levels via techniques like Western blotting, immunohistochemistry, and flow cytometry, aiding in the identification of p18INK4C loss or aberrant expression in tumor samples. In research, they help elucidate mechanisms of cell cycle deregulation and therapeutic resistance, particularly in cancers with CDKN2C defects. Clinically, p18INK4C expression patterns may serve as prognostic markers or inform targeted therapy strategies, such as CDK4/6 inhibitor treatments. However, antibody specificity and validation remain crucial to ensure accurate interpretation of p18INK4C’s role in disease pathogenesis and treatment response.
×
